DataMeds AI, Inc. (MEDS) stock analysis
Close on Nov 17, 2026Market cap $1.96MP/E –Yield –
StockData Score
Prices as of Nov 16, 2026How the score works
Weak1 of 30 checks passed
DataMeds AI passes 1 of the 30 checks behind our score; 19 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 1/6
- Growth
- 0/6
- Past performance
- 0/6
- Financial health
- 0/6
- Dividend
- 0/6
What stands out
P/S below the industry
DataMeds AI's price-to-sales of 0.26 is below the Wholesale Trade-non-durable Goods median of 0.29 (book value is negative, so we use sales).
What to watch
Return on capital under 10%
Return on invested capital was -153%, below the 10% that usually covers the cost of capital.
Interest not well covered
Operating income covers interest expense -6.2 times; we look for at least 5.
Debt not well covered by cash flow
Operating cash flow over the last twelve months equals -85.4% of total debt; we look for at least 20%.
Elevated bankruptcy risk
The Altman Z-score is -8.90; above 3 is the safe zone and below 1.8 the distress zone.
Valuation1/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/S below the industry
DataMeds AI's price-to-sales of 0.26 is below the Wholesale Trade-non-durable Goods median of 0.29 (book value is negative, so we use sales).
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.
Growth0/6
Revenue growth over 3 years
Needs three years of positive revenue.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing slower than the industry
Revenue grew -77.5% over the last twelve months; the Wholesale Trade-non-durable Goods median is -5.1%.
Guidance issued
The latest outlook (Q2-2026 revenue, May 19, 2026) was issued for the first time, so it neither adds nor takes away points.
Gross margin slipping
Gross margin was -92.1% over the last twelve months, against 7.9% a year earlier.
Past performance0/6
Return on equity
Needs positive equity and five years of results.
Return on capital under 10%
Return on invested capital was -153%, below the 10% that usually covers the cost of capital.
Return on equity below the industry
DataMeds AI's return on equity of -1707% is below the Wholesale Trade-non-durable Goods median of -6.0%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin against its history
Needs five years of revenue and net income.
Net margin below the industry
DataMeds AI's net margin of -565% is below the Wholesale Trade-non-durable Goods median of -13.1%.
Financial health0/6
Debt level
Needs debt and equity figures.
Debt trend
Needs a balance sheet from five years ago with positive equity.
Debt not well covered by cash flow
Operating cash flow over the last twelve months equals -85.4% of total debt; we look for at least 20%.
Interest not well covered
Operating income covers interest expense -6.2 times; we look for at least 5.
Short-term assets don't cover short-term debts
Current assets are 0.14 times current liabilities.
Elevated bankruptcy risk
The Altman Z-score is -8.90; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
DataMeds AI has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itWe don't publish a fair value for DataMeds AI. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/B at month end
- Wholesale Trade-non-durable Goods median 1.7
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Medium risk
- Average value traded per day
- $5.07M
- Value traded per 1% price move
- $48.71K
Downside
High risk
- Typical loss in a bad month
- 68.8%
- Volatility (annualized)
- 339%
- Sharpe ratio, 1 year
- -0.30
- Beta to the S&P 500 (5Y)
- 0.33
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2022 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +28.7% | – | – | – |
Returns and balance sheet
4 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2022 | FY2022 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 3545.2% | |
| Return on assets | – | – | -230.7% | |
| Current ratio | – | – | 0.09 | |
| Debt to equity | – | – | -1.89 | |
| Net debt to EBITDA | – | – | -0.26× | |
| Interest coverage | – | – | -20.5× | |
| Diluted shares | – | – | 1M |
Cash use needs five years of cash flow figures
DataMeds AI does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -433.9% | 0.53× | -15.37× | 3545.2% |
| FY2024 | -37.8% | 0.63× | 15.04× | -357.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero-$101.27M
- Cash generatingOperating cash flow above zero-$10.86M
- Return on assets improvedROA up on the prior year-2026.3% → -176.6%
- Earnings backed by cashOperating cash flow above net income-$10.86M vs -$101.27M
- Less leverageLong-term debt to assets fell20.0% → 41.4%
- Better liquidityCurrent ratio rose0.40 → 0.09
- No dilutionShare count did not rise1M → 1M
- Gross margin improvedGross margin up on the prior year9.75% → -27.54%
- More efficientAsset turnover rose53.58 → 0.41
See a number that looks wrong?